Project Grant R43CA177023

Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...

Grant Award Summary The National Cancer Institute awarded the University of Connecticut Health Center a $414,585 Project Grant on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform for noninvasive lung cancer detection. The grant supports development of PEAM-SEQ Version 2.0, an improved assay combining isothermal amplification, enzymatic cleavage, and...

This $431,220 National Science Foundation project grant supports the development of a novel part-brain, part-engineered gas sensor for noninvasive detection of lung cancer at Michigan State University from February 1, 2023 to January 31, 2028. The grant is funded through the NSF Directorate for Engineering's Engineering program (CFDA 47.041), which seeks to foster innovation and excellence in engineering research. Specifically, the university will develop a gas sensing device that utilizes...

Vigilant Laboratories LLC received a $1,021,347 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) to develop a commercializable point-of-care (POC) early detection test for oral cavity and oropharyngeal squamous cell carcinoma (OOPSCC). The award, effective September 1, 2025, through August 31, 2027, funds the optimization and advancement of patented biomarker technology combining CD44 (stem cancer cell marker), total...

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

Federal Grant Award Summary Darwin Biosciences, Inc. received a $399,998 Project Grant award dated July 17, 2025, from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an innovative point-of-need lung cancer screening device for low-resource settings. The company is adapting its existing handheld diagnostic platform—previously developed under a $12 million Department of Defense contract for pathogen detection—to identify lung cancer...

Federal Cooperative Agreement Award Summary The National Cancer Institute (NCI) awarded a $525,013 Cooperative Agreement to The University of Texas MD Anderson Cancer Center, effective September 1, 2025 through August 31, 2030, under the Cancer Detection and Diagnosis Research Program (CFDA 93.394). This award funds translational research to validate blood-based biomarkers for lung cancer risk assessment among individuals with no smoking history. The project will evaluate the predictive...

Federal Grant Award Summary Rumedical Nova LIMITED Liability Co received a $305,000 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) to develop a next-generation portable bio-chip platform for early-stage lung cancer diagnosis. The project, awarded July 15, 2026 with completion targeted for December 31, 2027, focuses on designing and validating a compact chip-based diagnostic...

New York University School of Medicine received a $703,227 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) awarded June 1, 2026, with a completion date of May 31, 2031. The grant supports development of an ultra-rapid droplet digital polymerase chain reaction (ddPCR) technology platform designed to deliver molecular-genetic profiling of cancer-driving mutations directly within the operating room during surgical resection...

The National Cancer Institute awarded a $244,228 Project Grant to the University of Texas MD Anderson Cancer Center to develop a proteomics-driven approach to accurately map patient tumor samples to preclinical models in lung cancer research under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The goal is to expand proteomic profiling of lung cancer patient-derived xenograft (PDX) models using reverse-phase protein arrays (RPPAs) to build a comprehensive...